Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 16/20 | 0.57 |
| ▸ | CDK7 | P50613 | 1/20 | 0.54 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.54 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4889660 | 0.87 | CDK8 (0.67) | CDK8CDK7CDK6 | |
| SCHEMBL4942948 | 0.86 | NAMPT (0.51) | MAPKAPK2MAP4K4 | |
| SCHEMBL31190971 | 0.86 | NAMPT (0.51) | MAPKAPK2MAP4K4 | |
| SCHEMBL13636100 | 0.85 | CDK8 (0.51) | CDK8CDK7CDK6MAPKAPK2 | |
| SCHEMBL29131710 | 0.84 | HPGD (0.59) | MAP4K4 | |
| SCHEMBL2414378 | 0.83 | NAMPT (0.44) | CDK8MAPKAPK2MAP4K4 | |
| SCHEMBL2413104 | 0.82 | CYP17A1 (0.45) | MAPKAPK2MAP4K4 | |
| SCHEMBL12362958 | 0.82 | MAP4K4 (0.48) | CDK8MAPKAPK2MAP4K4 | |
| SCHEMBL2410967 | 0.82 | CYP17A1 (0.45) | CDK8MAPKAPK2MAP4K4 | |
| SCHEMBL1477353 | 0.82 | CDK8 (0.63) | CDK8CDK7CDK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915295-B2 | Viricides; HIV antivirals effective against problematic drug escape mutants; N-[(1S,1aR,7bR)-4,7-difluoro-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-1-yl]-N'-[5-(4-(sulfonamido)phenoxy)-2-pyridinyl]urea | MEDIVIR AB (SE) | 2011-03-29 | — | — | US | disclosed |
| US-7915295-B2 | Viricides; HIV antivirals effective against problematic drug escape mutants; N-[(1S,1aR,7bR)-4,7-difluoro-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-1-yl]-N'-[5-(4-(sulfonamido)phenoxy)-2-pyridinyl]urea | MEDIVIR AB (SE) | 2011-03-29 | — | — | US | disclosed |
| US-7915295-B2 | Viricides; HIV antivirals effective against problematic drug escape mutants; N-[(1S,1aR,7bR)-4,7-difluoro-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-1-yl]-N'-[5-(4-(sulfonamido)phenoxy)-2-pyridinyl]urea | MEDIVIR AB (SE) | 2011-03-29 | — | — | US | disclosed |
| EP-1701942-B1 | NON-NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2009-12-09 | — | — | EP | disclosed |
| EP-1701942-B1 | NON-NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2009-12-09 | — | — | EP | disclosed |
| US-20080070951-A1 | Non-Nucleotide Reverse Transcriptase Inhibitors | MEDIVIR AB (SE) | 2008-03-20 | — | — | US | disclosed |
| US-20080070951-A1 | Non-Nucleotide Reverse Transcriptase Inhibitors | MEDIVIR AB (SE) | 2008-03-20 | — | — | US | disclosed |
| US-20080070951-A1 | Non-Nucleotide Reverse Transcriptase Inhibitors | MEDIVIR AB (SE) | 2008-03-20 | — | — | US | disclosed |
| EP-1701942-A1 | NON-NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005066131-A1 | NON-NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070951-A1 | Non-Nucleotide Reverse Transcriptase Inhibitors | RCOR1, RRM2, POLR1A | CDK8 126/4885CDK7 786/4885CDK6 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.